secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-266990
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 3.02, 2.01, 4.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron acquires Lung Therapeutics in stock deal, raises $18M via PIPE, appoints new COO
--------------------------------------------------------------------------------

- Acquired Lung Therapeutics for 344,566 shares of common stock and 20,140 shares of Series X Preferred; post-merger shares outstanding ~4.89M.
- Raised ~$18M in private placement with Bios Partners, Nantahala Capital, and others; includes Series X Preferred and warrants exercisable at $4.89/share.
- Dismissed PricewaterhouseCoopers as auditor effective upon merger close; PwC had included a going concern paragraph in prior reports.
- Appointed Brian Windsor, former Lung CEO, as President and COO; elected William Fairey and Alan Musso to the board.
- Jeffrey Bailey, Jodie Morrison, and William McKee resigned from the board; Josef von Rickenbach named chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/0001193125-23-266990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312523266990/d571974d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-266990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer